How Tirzepatide Compares to Other Weight Loss Medications
Tirzepatide versus other drugs
If you've been told to lose weight, the menu of options can feel overwhelming. Tirzepatide. Semaglutide. Phentermine. Contrave. Orlistat. Some are pills. Some are weekly injections. Some have been around for decades. Others are brand-new. The honest answer to "How does tirzepatide compare to other weight loss medications?" is this: in head-to-head trials, tirzepatide produces more weight loss than any other approved drug — but it's not the right choice for everyone, and it works best when a physician is guiding the plan. Below is a clear, evidence-based comparison written for patients across Northwest Louisiana who want to understand their options before making a decision.
The Big Picture: Where Tirzepatide Fits Among Weight Loss Medications
Today there are six FDA-approved medications most commonly prescribed for chronic weight management:
- Tirzepatide (brand name Zepbound) — weekly injection, FDA-approved for weight management in November 20234
- Semaglutide (brand names Wegovy and Ozempic) — weekly injection
- Liraglutide (brand name Saxenda) — daily injection
- Phentermine (often combined with topiramate as Qsymia) — daily oral pill
- Naltrexone-bupropion (brand name Contrave) — daily oral pill
- Orlistat (brand names Xenical and Alli) — oral capsule with meals
In large clinical trials, the average percent body weight lost over 12–18 months looks roughly like this:[1][1]
- Tirzepatide: about 20%
- Semaglutide: about 14%
- Phentermine/topiramate: about 9%
- Liraglutide: about 5%
- Naltrexone-bupropion: about 5%
- Orlistat: about 3%
Tirzepatide is, on paper, the most effective. But efficacy is only one piece of the picture. The right medication depends on your medical history, your goals, your tolerance for side effects, and whether you have a doctor who can monitor you carefully along the way.
How Tirzepatide Works (and Why It's Different)
Tirzepatide is the first weight loss medication that activates two gut hormone receptors at once — GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Every other GLP-1 medication, including semaglutide and liraglutide, activates only one. That second receptor matters: it appears to give tirzepatide an extra push on appetite and food intake, which translates into more weight lost in clinical trials.
In practical terms, tirzepatide does three things:
- Slows how quickly food leaves your stomach, so you feel full longer
- Reduces appetite signals from the brain, so cravings drop
- Improves how your body uses insulin, which helps blood sugar control
It's given as a weekly injection under the skin, starting at a low dose and stepping up over several weeks to a target of 5 mg, 10 mg, or 15 mg per week. The slow ramp-up is intentional — it gives your body time to adjust and reduces nausea.
Tirzepatide vs. the Other Major Weight Loss Medications
Here's how tirzepatide stacks up against each commonly used option.
Tirzepatide vs. Semaglutide (Wegovy / Ozempic)
This is the comparison patients ask about most often, and now we have a direct, head-to-head answer. The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, randomly assigned 751 adults with obesity to either tirzepatide or semaglutide for 72 weeks.[1] The results were clear:
- Average weight loss with tirzepatide: 20.2%
- Average weight loss with semaglutide: 13.7%
Tirzepatide patients were also more likely to hit major milestones — 10%, 15%, 20%, and even 25% body weight loss. Side effects were similar overall, but slightly fewer tirzepatide patients had to stop the medication because of nausea or other gut-related issues. For many patients, semaglutide is still an excellent choice — particularly when insurance coverage or supply makes it easier to access. But if pure weight loss potential is the goal, tirzepatide currently leads the field.
Tirzepatide vs. Liraglutide (Saxenda)
Liraglutide is the older daily-injection cousin of semaglutide. It's a GLP-1 medication too, but it's been on the market longer and works less powerfully. Average weight loss is around 5%. Because tirzepatide activates two receptors and only requires one shot per week, it has largely replaced liraglutide as a first-line choice for patients who can tolerate an injection. Liraglutide is still useful for some patients — including pediatric and adolescent patients in specific situations — but for most adults seeking significant weight loss, it's no longer the top pick.
Tirzepatide vs. Phentermine (and Phentermine/Topiramate)
Phentermine is one of the oldest weight loss medications still in use, originally approved in the 1950s. It's a stimulant — taken as a daily pill — that suppresses appetite. When combined with topiramate (sold as Qsymia), it's surprisingly effective: average weight loss of about 9%, with three out of four patients losing at least 5% of their starting weight.
Phentermine has real advantages. It's cheap, it's a pill, and it works quickly. But it also has limits. It can raise blood pressure and heart rate, which is a problem in patients who already have hypertension — and that includes most adults seeking weight loss in our area, where roughly 58% of adults with obesity also have high blood pressure.5 Phentermine is generally used short-term (a few months at a time), while tirzepatide is approved for long-term, ongoing use. For patients with cardiovascular risk factors, tirzepatide is often the safer long-term choice.
Tirzepatide vs. Naltrexone-Bupropion (Contrave)
Contrave is a daily oral pill that combines two older medications — naltrexone (used for addiction) and bupropion (used for depression and smoking cessation). Together, they reduce cravings and the reward feeling associated with food. Average weight loss is around 5%, with about 55% of patients losing 5% or more of their starting weight.[1]
Contrave can be a strong fit for patients whose weight is closely tied to emotional eating or food cravings — and for patients who also have depression and could benefit from the antidepressant effect. But the weight loss is modest compared with tirzepatide, and it's not the right choice for patients with a history of seizures or certain other medical conditions.
Tirzepatide vs. Orlistat (Xenical / Alli)
Orlistat works very differently. Instead of changing appetite or hormone signals, it blocks the absorption of dietary fat in the gut. Whatever fat you don't absorb passes through. The result is modest weight loss (around 3%) and well-known gastrointestinal side effects when patients eat fatty meals. Orlistat is the safest of the older options on paper — but for most patients pursuing meaningful weight loss, the efficacy gap with tirzepatide is too wide to ignore.
Side Effects, Safety, and Who's a Good Fit
Every weight loss medication has trade-offs. Here's what to know in plain language.
Tirzepatide and semaglutide share the same general side effect profile — nausea, mild stomach upset, occasional vomiting or diarrhea, especially in the first few weeks. Most patients feel these symptoms early, and they fade as the body adjusts. Rare but serious risks include pancreatitis, gallbladder issues, and a possible thyroid tumor risk seen in animal studies. These medications are not for patients with a personal or family history of medullary thyroid cancer or a condition called multiple endocrine neoplasia type 2.
Phentermine can cause a faster heart rate, higher blood pressure, insomnia, and dry mouth. It's not a good choice for patients with uncontrolled hypertension, heart disease, or anxiety disorders.
Contrave can cause nausea, headache, and constipation, and it shouldn't be used in patients with a history of seizures or uncontrolled hypertension.
Orlistat can cause oily stools, urgency, and gas — particularly when patients eat high-fat meals. It can also interfere with the absorption of fat-soluble vitamins, so a daily multivitamin is recommended.
The right medication depends on your full medical history — not just your weight. That's exactly the kind of decision a primary care doctor with time to talk to you should be making with you.
Why Physician-Led Care Matters — Especially in the Ark-La-Tex
Here's a reality of the current weight loss landscape: tirzepatide and semaglutide are everywhere online. Telehealth companies, med spas, and compounded-medication suppliers are advertising these drugs aggressively, often without a real physical exam, real lab work, or real ongoing follow-up. That's a problem.
These are powerful medications. Used correctly, with a doctor monitoring you, they're remarkably safe and effective. Used without monitoring, they can hide real medical problems, cause preventable side effects, and leave patients without help when something goes wrong.
At Shreveport Direct Care, we run a physician-led, medically supervised weight loss program for patients across Shreveport, Bossier City, and the broader Ark-La-Tex. Dr. Pat F. "Ricky" Bass III, MD, MS, MPH, is dual board-certified in Internal Medicine and Pediatrics. Our weight loss patients get a full medical workup, real lab monitoring, real conversations about nutrition and movement, and direct text or email access to Dr. Bass when questions come up between visits — all included in your flat monthly membership. There are no rushed visits, no copays, and no surprise bills. Modern Medicine. Old-School Experience.
Ready to Find the Right Weight Loss Plan for You?
Ready to get started with a physician-led weight loss plan? Schedule a free meet-and-greet with Dr. Bass and find out if our program is right for you — whether that includes tirzepatide, another medication, or simply a smarter plan than what you've tried before.
- Phone/Text: 318-588-7060
- Email: info@shreveportdirectcare.com
FAQs
1. What is tirzepatide? Tirzepatide is a once-weekly injectable medication that activates both GIP and GLP-1 receptors to reduce appetite and food intake. It was FDA-approved for chronic weight management in November 2023 under the brand name Zepbound, and it's also approved for type 2 diabetes under the brand name Mounjaro.
2. How is tirzepatide different from semaglutide? Tirzepatide activates two gut hormone receptors (GIP and GLP-1) while semaglutide activates only one (GLP-1). In a head-to-head trial, tirzepatide produced an average of 20.2% body weight loss versus 13.7% for semaglutide over 72 weeks, making it the most effective weight loss medication currently approved.
3. Is tirzepatide better than older weight loss pills like phentermine or Contrave? On weight loss alone, yes — tirzepatide produces about double the weight loss of phentermine/topiramate and roughly four times the weight loss of Contrave. But the right medication depends on your medical history, cardiovascular risk, and ability to tolerate an injection. Older oral medications still have a role, especially when GLP-1s aren't appropriate or accessible.
4. What are the most common side effects of tirzepatide? Nausea, mild stomach upset, constipation, and occasional vomiting or diarrhea — most often during the first few weeks as the dose is increased. These usually fade with time. Rare but serious risks include pancreatitis, gallbladder problems, and a possible thyroid tumor risk seen in animal studies.
5. Who shouldn't take tirzepatide? Patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN 2), patients with severe gastrointestinal disease, and pregnant patients should not take tirzepatide. Patients with a history of pancreatitis or gallbladder disease should discuss the risks carefully with their doctor.
6. How do I get tirzepatide safely in Shreveport, Bossier City, or the Ark-La-Tex? The safest path is through a physician-led program that includes a full medical workup, lab monitoring, and ongoing follow-up. Schedule a free meet-and-greet with Shreveport Direct Care to discuss whether tirzepatide is right for you and how our medically supervised weight loss program works.
References
Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine. May 2025. (SURMOUNT-5 trial: 20.2% weight loss with tirzepatide vs. 13.7% with semaglutide over 72 weeks; lower GI-related discontinuation with tirzepatide.)
Eli Lilly and Company. FDA Approves Lilly's Zepbound (tirzepatide) for Chronic Weight Management. November 8, 2023. (FDA approval date and indications for Zepbound.)
U.S. Food and Drug Administration. Zepbound (tirzepatide) Prescribing Information. FDA. 2024. (Mechanism of action, dosing, contraindications, and safety profile.)
Khera R, Murad MH, Chandar AK, et al. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-Analysis. JAMA / Obesity. 2016. (Comparative weight loss data for phentermine/topiramate, liraglutide, naltrexone-bupropion, and orlistat.)
American Heart Association. Trends in Obesity Prevalence Among Adults With Hypertension in the United States, 2001 to 2023. Hypertension. 2024. (58% obesity-hypertension overlap in U.S. adults.)
Centers for Disease Control and Prevention. Adult Obesity Facts. CDC. (U.S. and Louisiana adult obesity prevalence.)
Shreveport Direct Care is a direct primary care practice serving adults and children in Shreveport, Bossier City, and surrounding communities in Northwest Louisiana. Dr. Pat "Ricky" Bass III is board-certified in Internal Medicine and Pediatrics.